Compare Natera Inc. Common Stock (NTRA) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SkyWest Inc — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while SkyWest Inc trades at $90.69 (market cap $3.59B). The key difference: Natera Inc. Common Stock is far larger — about 15.9× SkyWest Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SkyWest Inc for 8 Days on average.
| NTRA | SKYW | |
|---|---|---|
Market Cap | $57.03B | $3.59B |
Volume | 1,131,157 | 419,815 |
Sector | Health | Industrials |
52-Week High | $425.64 | $115.94 |
52-Week Low | $179.42 | $78.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $56.18B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SkyWest (SKYW) trades at $94.52, down 0.53% with a bearish technical signal despite positive analyst sentiment. The stock shows mixed earnings performance with a recent Q1 2026 beat but Q2 2026 miss, while maintaining solid fundamentals including a 9.78% net income margin and attractive valuation at 9.39 P/E. Recent news highlights fleet modernization efforts and expanding flying agreements as growth catalysts amid cost pressures.
The stock presents a compelling value opportunity with 58.8% analyst buy ratings and $112 consensus target, offering 18.5% upside potential. However, technical weakness and executive stock sales create near-term headwinds. Long-term prospects remain positive driven by operational improvements and strategic partnerships, though investors should monitor cost management and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
